Adalimumab Biosimilar Update: Shanghai Henlius Biotech’s Approval in China and Celltrion’s Positive Opinion in the EU

Published date15 December 2020
Subject MatterChina,EU,Prescription Drugs,Biosimilars,China FDA,Pharmaceutical Industry,Celltrion,European Medicines Agency (EMA)
Law FirmGoodwin

To continue reading

Request your trial

VLEX uses login cookies to provide you with a better browsing experience. If you click on 'Accept' or continue browsing this site we consider that you accept our cookie policy. ACCEPT